Meet the Ribometrix team, where every individual is valued as part of a collaborative community sharing a common focus on advancing the field of modulating RNA biology to discover and develop transformative small-molecule drugs.
Careers
Build Your Career at Ribometrix
Ribometrix is committed to delivering on the promise of addressing human disease through novel scientific insight into RNA biology. Broadly, our discovery strategy includes directly targeting RNA, RNA-protein interactions, and RNA degradation.
We are a team of individuals driven by science, the spirit of innovation, collaboration, empowerment, and integrity who are committed to the goal of helping patients with our novel therapeutic approach.
If you are looking for an opportunity to drive cutting-edge science, collaborate with great people, and ultimately help patients in need, then Ribometrix is a place where you can thrive.
2024 Great Place to Work Award Winner
-
Our Mission
Leveraging RNA expertise to discover and develop transformative small-molecule drugs.
-
Our Vision
We are committed to improving the lives of patients and families by developing therapies through innovative science.
-
Our Values
Collaboration
We seek help when we need it and provide support when we can.
Integrity
We act with respect, sincerity, and transparency.
Innovation
We create with intent.
Empowerment
We are accountable for our actions and results.
Resilience
We conquer with persistence and adaptability.
Community
We foster camaraderie with shared purpose, values, and goals.
What do our employees look forward to when they come to work each day?
Benefits & Perks
We support you and your career with comprehensive benefits that make life easier and more enjoyable.
Ribometrix Leadership & Team
Our Latest Updates
View All News-
Ribometrix Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
-
Ribometrix To Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
-
Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024